Hepatocellular carcinoma is one of the leading causes of cancer death in the world. To understand the cellular changes associated with transformation of hepatocytes to the malignant state, we have made several libraries of monoclonal antibodies against the hepatocellular carcinoma cell line FOCUS and have found six antibodies (AF-20, SF-25, SF-31, SF-90, XF-4, and XF-8) that recognize antigens expressed at consistently higher levels on hepatoma cells. We have studied malignant and nontransformed liver tissue from the same individual by using direct '251-labeled antibody binding and immunoperoxidase staining techniques. For each of these antibodies, we found striking increases in antigen expression on the transformed tissues. These antigens were found to be expressed throughout the tumor and on distant metastases, with little, if any, expression on the nontransformed adjacent liver. These antibodies demonstrate that hepatic transformation may be accompanied by stereotyped and predictable antigenic changes. The uniformity of such antigenic changes suggests an association between these cell-surface alterations and the malignant transformation process. Monoclonal Antibodies Production. Immunizing cells were grown from the second passage of the FOCUS cell line developed in our laboratory and were harvested with EDTA. Six-week-old BALB/c mice were immunized by intraperitoneal injection of 4.0 x 106 FOCUS cells emulsified in 50% (vol/vol) complete Freund's adjuvant, followed 6-10 weeks later by intravenous injection of 4.0 x 106 cells in 0.2 ml of PBS. Three days later, mouse spleen cells were fused with either SP20, NS1, or X63 mouse myeloma cells with 30% (wt/vol) polyethylene glycol. Hybridomas were selected and maintained as described (2). Screening for antibodies was performed by the indirect binding assay described below, and antibody-producing colonies were cloned twice by limiting dilution. Ascites fluid was prepared by injection of hybridoma cells intraperitoneally into 2,6,10,14-tetramethylpentadecane (pristane; Aldrich)-primed BALB/c mice. Purification and iodination of monoclonal antibodies were performed as described (2) .
Epidemiological, serological, and molecular biological evidence links chronic hepatitis B virus infection to acquisition of human hepatocellular carcinoma (HCC). Since there are high chronic carrier rates of hepatitis B virus in many parts of the world, especially in Asia and Africa, HCC is one of most common human malignancies (1) . Despite the preponderance of HCC, progress in elucidating the mechanisms of malignant hepatocyte transformation at either the cellular or molecular level has been slow.
One method of studying the transformed phenotype is to search for and characterize alterations in the antigenic composition of the cell surface. Thus, we created a large library of antibodies reactive against a HCC cell line. We then selected antibodies that preferentially bind HCC-derived cells for use in a systematic analysis of antigenic variation in vivo between malignant and normal human liver tissue. To control for antigenic variation between individuals, paired sets of HCC and adjacent nontransformed liver tissue from South African hepatoma patients were employed. By using immunoperoxidase staining and a radioimmunoassay that measures binding of monoclonal antibodies to antigens on cell membranes, we studied the levels of antigen expression on these paired sets of tissue. Some of these antigens were then further characterized by immunoblotting, metabolic labeling, and immunoprecipitation.
MATERIALS AND METHODS
Tissues and Cell Lines. Mycoplasm-free FOCUS, PLC/ PRF/5, SK Hep-1, Mahlavu, Hep G2, Hep 3B, and Vero cells were harvested from monolayer cultures by washing with isotonic phosphate-buffered saline (PBS) followed by treatment with EDTA in the absence of trypsin. Leukocytes (WBC) were isolated from fresh human blood by Ficoll/Hypaque centrifugation. Cells used in the binding assays were frozen in 15% (vol/vol) glycerol and stored at -80'C. Hepatoma and adjacent nontransformed liver tissues were obtained from surgically resected or autopsy specimens from South Africa, frozen in liquid nitrogen, and stored at -800C.
Monoclonal Antibodies Production. Immunizing cells were grown from the second passage of the FOCUS cell line developed in our laboratory and were harvested with EDTA. Six-week-old BALB/c mice were immunized by intraperitoneal injection of 4.0 x 106 FOCUS cells emulsified in 50% (vol/vol) complete Freund's adjuvant, followed [6] [7] [8] [9] [10] weeks later by intravenous injection of 4 .0 x 106 cells in 0.2 ml of PBS. Three days later, mouse spleen cells were fused with either SP20, NS1, or X63 mouse myeloma cells with 30% (wt/vol) polyethylene glycol. Hybridomas were selected and maintained as described (2) . Screening for antibodies was performed by the indirect binding assay described below, and antibody-producing colonies were cloned twice by limiting dilution. Ascites fluid was prepared by injection of hybridoma cells intraperitoneally into 2,6,10,14-tetramethylpentadecane (pristane; Aldrich)-primed BALB/c mice. Purification and iodination of monoclonal antibodies were performed as described (2 Immunoperoxidase Staining. Frozen tissue specimens embedded in OCT compound (Miles Scientific, Naperville, IL) were sectioned, fixed to slides with -200C acetone, and equilibrated in PBS. The slides were stained with the Vectastain ABC kit (Vector Laboratories, Burlingame, CA). Briefly, the slides were incubated in dilute horse serum for 20 min, dried by blotting, then incubated overnight at 40C with monoclonal antibody (1:100-1:1000 dilution of ascites fluid in PBS), and washed with PBS. The slides were sequentially incubated in biotinylated anti-mouse IgG (1 hr), 0.3% H202 in methanol (20 min), and avidin-peroxidase complex (1 hr), with PBS washings between each step. The slides were incubated in 0.1 M Tris phosphate buffer (pH 7.5) containing 0.005% H202 and 3,3'-diaminobenzidine (0.5 mg/ml) until the positive control slide showed evidence of reaction. After washing, the slides were counterstained with methyl green or hematoxilin.
Immunoblotting. Tissue samples were homogenized with a Potter-Elvehjem homogenizer in ice-cold 0.1 M Tris-HCl buffer containing 0.1 M NaCl and 0.1% aprotinin. Nonidet P-40 was added to 0.5% and incubated for 15 min. The lysate was centrifuged for 10 min at 10,000 x g. Washed cells were lysed directly in the Nonidet P-40 solution, then centrifuged for 15 min at 1500 x g. The supernatants were incubated at 95°C for 5 min in 0.025 M Tris HCI buffer containing 0.1% NaDodSO4 and 20% (vol/vol) glycerol, then loaded onto 10% NaDodSO4/polyacrylamide gels and separated as described by Laemmli (4 Immunoprecipitation. Solid-phase supports were prepared by covalently binding monoclonal antibodies to protein A-Sepharose beads (6, 7) . Cell lysates were preadsorbed by incubating for 1 hr at 40C with formalin-fixed Staphylococcus aureus. Additional adsorption was performed for 2 hr at 4°C by using beads coated with an irrelevant IgG monoclonal antibody. Immunoprecipitation was carried out by incubating the adsorbed cell lysate with monoclonal antibody-coated beads for 24 hr at 4°C.
RESULTS
Binding Studies. We generated 140 hybridomas producing antibodies reactive to FOCUS cells. The FOCUS cell line was chosen because it appears to be a good model for studying hepatitis B virus-associated HCC on the basis of enzymatic and protein synthetic capabilities, solid tumor morphology, and the presence of a single hepatitis B virus integration site (8, 9) . For this study we produced monoclonal antibodies against cells grown from the second passage of the FOCUS cell line to represent the antigenicity of the original primary HCC tumor as faithfully as possible.
Seven monoclonal antibodies (AF-20, SF-25, SF-31, SF-58, SF-90, XF-4, and XF-8) were selected on the basis of their binding specificities. The signal/noise ratios for indirect binding of these antibodies to six HCC-derived cell lines, to the Vero cell line, and to normal peripheral WBC are shown in Fig. 1 . Four antibodies (AF-20, SF-25, SF-31, and SF-90) bound well to all six HCC cell lines, whereas XF-4 bound to four out of six, and XF-8 bound to four out of five (the sixth HCC cell line was not tested). In contrast to these high rates of binding to HCC cell lines, SF-58 bound to only two of the six HCC cell lines. Antibodies SF-31 and SF-90 bound weakly to Vero and insignificantly to WBCs (signal/noise ratio < 2.5). None of the other antibodies bound to either Vero or WBCs. Thus, with the exception of SF-58, these antibodies bound most or all of the HCC cell lines with minimal or no binding to two nonmalignant cell types.
Competitive inhibition of radiolabeled antibody binding with unlabeled antibody for blocking showed that for all seven antibodies, >90% of the observed binding was specific and could be inhibited. An example of this competitive inhibition for AF-20 is shown in Fig. 2 . Other competitive inhibition studies have shown that either SF-31 or SF-90 could completely inhibit binding of the other, suggesting that these two antibodies may recognize the same or adjacent epitopes. The binding of the remaining five antibodies was not blocked by the other antibodies, suggesting that each appears to define a separate membrane-associated epitope (data not shown).
An immunoassay was developed to measure radiolabeled monoclonal antibody binding to membrane preparations derived from hepatoma tissue and adjacent uninvolved liver from six patients. Protein concentrations were standardized, and specific binding was determined by subtracting the nonspecific binding (i.e., residual binding in the presence of excess inhibiting unlabeled antibody) from the total binding (i.e., binding in the presence of excess noninhibiting cold antibody). Fig. 3 is a summary of the antibodies binding to all six HCC/nontransformed liver sets. AF-20, SF-31, SF-90, XF-4, and XF-8 had a striking preference for binding to HCC with significant increases in antigen expression on HCC tissue compared to adjacent nontransformed liver tissue. Fig. 4 showed an entirely different binding pattern (Fig. 3) 
DISCUSSION
Due to the recognized importance of cell surface molecules in regulating cell growth, replication, differentiation, and responsiveness to exogenous information and control (11, 12) , several studies of hepatic transformation have centered on generating monoclonal antibodies that recognize antigens present on HCC-derived cell lines. Furthermore, since cellsurface antigenic variations may be manifestations of and thus markers for gene activation or inactivation, it is hoped that such an approach will eventually produce the tools necessary to elucidate some of the genetic changes associated with malignant transformation. This approach has led to the development of several antibodies that recognize HCCassociated antigens (5, (13) (14) (15) (16) .
The antibodies presented here appear to differ from the reported HCC-selective monoclonal antibodies. Binding specificities, molecular weights, and competitive inhibition experiments (data not shown) have demonstrated that three antibodies described by this laboratory (P215457, PM4E9917, and P232524) do not recognize the same antigens (5, 13) . Two other antibodies (K-PLC2 and K-PLC3) bind only to the PLC/PRF/5 cell line and probably also recognize dissimilar antigens (14) . Of the remaining three antibodies, 699B-C3 recognizes a 90-kDa membrane protein present on several cell lines (15) , and 833-1C4 and K-PLC1, respectively, recognize phospholipid and 115-kDa glycoprotein antigens present on HCC tissue and cell lines but not on normal liver (14, 16 (Fig. 5) . The strong association between malignant transformation and the high level of expression of these antigens suggests that they may play an important role on the surface of hepatoma cells. In contrast, SF-58 recognizes an antigen that shows consistent decreases in expression on the transformed tissue with high levels of expression on normal liver tissue.
Studies showing antibody binding to live cells demonstrated that these antibodies recognize cell surface epitopes (Fig. 1) . SF-31 and SF-90 recognize the same two 40-kDa and 50-kDa proteins and can competitively inhibit the binding of the other. AF-20 recognized three closely similar antigens of 116-120 kDa, whereas SF-25 recognized a 125-kDa protein (10) . The AF-20 and SF-25 antigens are labile and subject to inactivation by mild fixation, denaturation, and detergents. The SF-58, XF-4, and XF-8 antigens have not yet been molecularly characterized.
Therefore, we have identified six HCC-selective antibodies and one normal liver-selective antibody. Of general interest, these seven antibodies demonstrate that human hepatic transformation is accompanied by significant and measurable antigenic changes. Furthermore, alterations in the hepatocyte antigenic composition are predictable and found consistently in all paired comparisons of transformed and adjacent nontransformed tissue studied to date. Such uniformity in antigenic change emphasizes that there is a strong association of these antigens with the cellular transformation process. Further characterization of these antigens and attempts to identify others will permit a definition of cell surface changes associated with the malignant phenotype.
This work was supported in part by Grants CA-35711, AA-02666, and HD-20469 from the National Institutes of Health. J.R.W. is the recipient of a Research Career Scientist Development Award AA-00048. P.M. is the recipient of a fellowship from Association pour la Recherche sur le Cancer.
